Norwegian Childhood Diabetes Registry: Childhood onset diabetes in Norway 1973-2012

Torild Skrivarhaug

Norwegian Childhood Diabetes Registry, Department of Paediatric Medicine, Women and Children’s Division, Oslo University Hospital

Correspondence: Torild Skrivarhaug, Department of Paediatric Medicine, Oslo University Hospital, PB 4950, 0424 Oslo
E-mail: torild.skrivarhaug@medisin.uio.no  Telephone: +47 22118765 / 23015648  Telex: +47 22118663

ABSTRACT

The Norwegian Childhood Diabetes Registry (NCDR) is a prospective, population-based, nationwide registry which systematically register all incident cases of childhood diabetes, and systematically monitors the outcome of diabetes care in children and adolescents. NCDR includes data on childhood onset diabetes since 1973, and diabetes care outcome since 2001. NCDR was founded with the following objectives: To improve the diagnostics, classifications and treatment of childhood-onset diabetes, surveillance of incidence of diabetes in children and adolescents, surveillance of quality of diabetes care in Norwegian paediatric departments, and to stimulate to research in diabetes.

INTRODUCTION

Diabetes mellitus with onset in childhood represents one of the most frequent chronic diseases in children and young adults. The incidence of childhood onset type 1 diabetes in Norway is the third highest in the world, next to Finland and Sweden (1). The incidence has been steadily increasing since 1973 until 2009 when a peak in incidence was observed: 36 per 100,000 year (2-4). In Norway, type 1 diabetes is the second most common chronic disease in children age 0-14 years and it represents more than 98% of all diabetes in children younger than 15 years. Yearly approximately 290-330 children are diagnosed with type 1 diabetes in Norway.

Type 1 diabetes is related to a significant burden to the patient and to the society because most cases require lifelong treatment with insulin as well as day-to-day monitoring and treatment of complications. The disease has an increased risk of late complications such as renal disease, blindness, amputations, heart disease and stroke. Despite advances in treatment, type 1 diabetes is still associated with considerable premature mortality, resulting from acute and chronic complications of diabetes (5-8), even in societies with unrestricted access to the treatment of diabetes and its complications.

Several studies provide clear evidence that better metabolic control, as measured by a lower HbA1c level, is associated with fewer and delayed microvascular and macrovascular complications (9-13). Follow-up data from the Diabetes Control and Complications Trial (DCCT) indicated that 5-7 years of poor glycemic control, even during adolescence and young adulthood, results in an increased risk of complications in the subsequent 6-10 years (14). HbA1c reflects level of glycemia over the preceding 4-12 weeks, weighted toward the most recent four weeks (15). HbA1c monitoring has been shown to be the most useful measure in evaluating metabolic control and is the only measure for which good data are available in terms of its relationship with later microvascular and macrovascular complications (9,10).

NORWEGIAN CHILDHOOD DIABETES REGISTRY

Establishment and collection of data

Norwegian Childhood Diabetes Registry (NCDR) was established in 2006, and is financed by the South-Eastern Norway Regional Health Authority. The Women and Children’s Division, Oslo University Hospital is responsible for the daily operation, data management and security. An informed consent is obtained from each patient and/or the parents, before the patient is registered. NCDR has a prospective registration of data; both incident cases and clinical data from yearly examinations of all children and adolescents with diabetes treated in paediatric departments in Norway. In addition, NCDR contains data from two earlier diabetes registries/research projects; The Norwegian Diabetes Registry and The Norwegian Childhood Diabetes and Quality project. After the merger to NCDR these two registries stopped existing as independent research registries/projects.

Aims of the Norwegian Childhood Diabetes Registry

NCDR was founded with the following objectives:

- To improve the diagnostics, classifications and treatment of childhood-onset diabetes.
- Surveillance of quality of diabetes care in Norwegian paediatric departments measured by HbA1c, acute complications, and implementation of screening procedures for late complications and associated diseases according to national and international guidelines for childhood diabetes (16).
• To ensure equal treatment to all children and adolescents with diabetes, and to stimulate to research in diabetes.

The Norwegian Childhood Diabetes Study Group
NCDR is based on the Norwegian Childhood Diabetes Study Group, a network of all paediatricians and diabetes nurses treating children and adolescents with diabetes in paediatric departments. Since 2008 all paediatric departments in Norway are reporting to NCDR.

Main tasks
The NCDR has four main tasks:
1) To collect standardized data from; i) incident cases, ii) yearly examinations (starting one year after diabetes onset).
2) To analyse and benchmark the data.
3) To report the data back to the paediatric departments and to the Health authorities.
4) To maintain and further develop the network for quality work among paediatric departments to ensure equal diabetes treatment throughout Norway.

The Norwegian childhood diabetes registry are collecting the following data
New onset cases
NCDR includes registration of all new onset cases of childhood diabetes. Data go back to 1973, collected retrospectively (2), and prospectively from 1989. From 2002 blood samples are collected together with clinical data in incident cases. Norway has since 1989 been one of the 23 EURODIAB centres reporting incidence of childhood onset type 1 diabetes in Europe (17). The completeness of ascertainment in NCDR is calculated to 91% (18).

Annual data on diabetes care
NCDR also includes prospectively collected, yearly, standardized clinical data on diabetes care, including blood samples. Quality indicators are benchmarked. Sampling of data on diabetes care started with a few paediatric departments in 2001, including all the paediatric departments from 2008 (Table 1). Data are collected on a case record form based on the World Health Organization Basic Information Sheet for children and adolescents. HbA1c is determined for all participants by high-performance liquid chromatography (Tosoh G7; Tosoh Europe N.V., Belgium), at the same central DCCT-standardized laboratory (OUS, Aker).

The adherence rate on annual reporting has been rising from the start in 2001 until 95% in 2010 and 2011. In 2011 all the paediatric departments participated with a total of 2567 patients; 98% type 1 diabetes (2520/2567), 0.5% type 2 diabetes (12/2567), 1.1% MODY (28/2567), 0.3% other types of diabetes (8/2567).

Quality indicators for diabetes care
The Norwegian paediatric departments are anonymous benchmarked for the following quality indicators:

![Figure 1. Incidence of Type 1 diabetes in children 0-14 years in Norway, during 1973-2011. Norwegian Childhood Diabetes Registry.](image-url)

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of paediatric clinics (n)</th>
<th>Number of participants (n)</th>
<th>Completeness of participants in eligible patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>8</td>
<td>470</td>
<td>–</td>
</tr>
<tr>
<td>2002</td>
<td>20</td>
<td>963</td>
<td>–</td>
</tr>
<tr>
<td>2003</td>
<td>22</td>
<td>1129</td>
<td>–</td>
</tr>
<tr>
<td>2004</td>
<td>23</td>
<td>1417</td>
<td>74</td>
</tr>
<tr>
<td>2005</td>
<td>25</td>
<td>1664</td>
<td>75</td>
</tr>
<tr>
<td>2006</td>
<td>25</td>
<td>1721</td>
<td>76</td>
</tr>
<tr>
<td>2007</td>
<td>26</td>
<td>1836</td>
<td>82</td>
</tr>
<tr>
<td>2008</td>
<td>26</td>
<td>2059</td>
<td>89</td>
</tr>
<tr>
<td>2009</td>
<td>26</td>
<td>2341</td>
<td>93</td>
</tr>
<tr>
<td>2010</td>
<td>27</td>
<td>2457</td>
<td>95</td>
</tr>
<tr>
<td>2011</td>
<td>27</td>
<td>2567</td>
<td>95</td>
</tr>
</tbody>
</table>
HbA1c, severe hypoglycemia, hospitalization for diabetes ketoacidosis, completed screening of late complications (retinopathy, nephropathy, blood pressure, lipids), completed screening for associated diseases (celiac disease, hypothyroidism, hyperthyroidism). Screening for late complications and associated diseases is done according to ISPAD consensus guidelines (16).

**DATA FROM THE NORWEGIAN CHILDHOOD DIABETES REGISTRY**

Type 1 diabetes represents more than 98% of all diabetes registered in NCDR.

1) **Data at presentation of childhood onset type 1 diabetes**

**Incidence of childhood onset type 1 diabetes**

The incidence of type 1 diabetes diagnosed before 15 years has been increasing globally (1). The average increase per year has been 2.5-3.0 worldwide, however, wide variation in increase of type 1 diabetes has been well characterized by the DIAMOND project group (19) and from the EURODIAB study group (17,20). The increase in incidence has not been uniform; several countries are showing periods of both less rapid and more rapid increase (17), and some reports a reverse trend (21). There is indication that the incidence is rising more steeply in some of the low prevalence countries (1,20). Both Finland and Sweden have reported a decreasing incidence in recent years (21,22).

Norway has had a steadily increasing incidence from 19.0 per 100,000 years in 1973 until 2009 when a peak in incidence was observed; 36 per 100,000 years (2-4). The increase in this period has however not been uniform; it includes both periods with more rapid increase and periods with no increase at all (2004-2008). After 2009 the incidence has declined, and in 2011 it was 31 per 100,000 years (23). The decrease has to be interpreted with caution, since it is still possible that this is a temporary phenomenon.

In childhood onset type 1 diabetes, the male-to-female ratio has been reported to vary with the incidence level of the population under study. A slight excess of male patients was more often noted in high incidence countries (22,24). Also in Norway there is a slight excess of boys. Several European studies have suggested that the increase in incidence of childhood onset type 1 diabetes, in relative terms, are greatest among children aged 0-4 years (25-28). This has never been the case in Norway, where the highest increase always has been in the age group 10-14 years.

It is indicated that the increasing incidence of childhood type 1 diabetes is not attributable to a global increase in disease incidence, but rather to earlier manifestation (29,30). It is suggested that genetic susceptibility to develop type 1 diabetes has decreased over time due to an increasing environmental pressure and that this results in a higher disease progression rate in younger individuals. Norway has no complete registration of incident cases with type 1 diabetes after the age of 15 years, and cannot contribute with data to this discussion.

**Diabetic ketoacidosis at presentation of childhood onset type 1 diabetes**

Diabetic ketoacidosis (DKA) is the leading cause of mortality in children with type 1 diabetes worldwide, and is associated with increased morbidity and healthcare expenditure. DKA is metabolic derangement characterised by the triad of hyperglycaemia, acidosis and ketosis that occurs in the presence of very low levels of effective insulin action. The worldwide variation in incidence of type 1 diabetes in children has been well characterised, but there is less evidence concerning the frequency of DKA at diagnosis of type 1 diabetes. A study from Europe indicated that the frequency of DKA at diagnosis varied from 11% to 67% (31). The first published data from Norway on DKA at presentation of type 1 diabetes, reported that 18.0% of the children had DKA; 17.0% of the boys and 18.3% of the girls. Divided in age groups the proportions of patients with DKA were: age 0-4 years 16.3%, age 5-9 years 11.3%, age 10-14 years 21.9%. The severity of DKA is categorized by the degree of acidosis (16): 41% of the patients had mild DKA, 35% had moderate DKA and 23.5% had severe DKA (32).

2) **Annual data on diabetes care. The following data is from patients with type 1 diabetes**

**HbA1c**

The grand mean HbA1c of all clinics improved significantly (p < 0.01) during the first 5-yr period (2001-2005) from 8.6% to 8.2% (33). In 2011, the grand mean HbA1c was 8.3% (range 7.6-8.9). Before benchmarking the different paediatric departments, the mean HbA1c in each department is adjusted for gender, age and diabetes duration. In 2011, 97% of the patients had a centrally analysed HbA1c.

**Severe hypoglycemia**

The term severe hypoglycemia is defined as episodes of hypoglycemia were the patient is semiconscious or unconscious with or without seizures (16). In 2011, severe hypoglycemia was reported in 6.3% of the patients, 1.3% had more than one event. Stratified into gender; 6.5% of the males (1.6% > 1 event), and 6.3% of the females (1.0% > 1 event), had experienced severe hypoglycaemia during 2011 (34).

**Hypertension with diabetic ketoacidosis**

Diabetic ketoacidosis (DKA) is defined as hospitalized with pH < 7.3 or bicarbonate < 15 mmol/l. In 2011, 4.8% of the patients were hospitalized with DKA, 0.6% had more than one event. Stratified into gender; 4.7% of the males (0.5% > 1 event) and 5.1% (0.7% > 1 event) of the females were hospitalized with DKA (34).

**Nephropathy screening**

Nephropathy screening includes measurement of urinary albumin excretion rate in either 24h or overnight
urine collection or by urine albumin/creatinine ratio. Urine-albumin measurements are done at a local laboratory by standard sensitive immunological methods. In 2011, urine samples were collected from 86% of the patients. 96% were screened accordingly to ISPAD consensus guidelines (16). Persistent microalbuminuria was found in 0.6% of the patients, 1.0% had albuminuria (23).

Retinopathy screening
The retinopathy screening includes fundus examination (fundoscopy) in mydriasis (after pupil dilation) performed by experienced local ophthalmologist. In 2011, 41% of the patients had retinopathy screening. 68% were screened accordingly to ISPAD consensus guidelines (16). No one had laser treatment. 0.3% had non proliferative diabetes retinopathy (23).

Intensified insulin treatment
Intensified insulin treatment refers to either using insulin pump or four or more insulin injections per day. The insulin treatment has changed during the years. In 2001, 9% of the youths in NCDR used insulin pump and 33% were on mix insulin. In 2011, 59% used insulin pump, only 0.3% was on mixed insulin. Less than 5% use one to two daily insulin injections (23).

Smoking
A significant decline in the incidence of smoking among patients above 15 years was observed from 2001 (18%) to 2005 (5%) (p < 0.001) (33). Since 2006 the incidence has been rather stable with 6% in 2010 and 2011 (23). The topic of how important it is to encourage young people to stop smoking or never start smoking has been discussed in NCDR annual meetings.

ANNUAL MEETING IN NORWEGIAN CHILDHOOD DIABETES REGISTRY
Difference in outcome among treatment centres revealed by the Benchmarking centre report, provide a basis for discussion. Likewise has the screening for late complications and associated diseases according to international guidelines (16), improved following discussions at the annual NCDR meeting, leading to changes in screening assessments. This illustrates the value of a national quality circle in the NCDR.

REFERENCES


